Stifel Raises Hinge Health (HNGE) Price Target to $130
Key Points
- Stifel increased its price target for Hinge Health from $115 to $130, maintaining a Buy rating on the stock.
- Stifel's $130 price target implies 16.70% upside from Hinge Health, Inc.'s ($HNGE) current $111.40 share price.
- Hinge Health shares recently traded at about $111.40, which is above the 50-day moving average by 16.6% and the 200-day moving average by 70.4%.
- The company reported trailing twelve-month revenue of $720.1 million and a net margin of 15.1%, with earnings expected on November 2, 2026.
Get Hinge Health text alerts
We text you when insiders, Congress, analysts or big funds move on $HNGE.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures
On October 26, 2026, Stifel raised its price target on Hinge Health, Inc. (NYSE: HNGE) to $130 from $115 while maintaining a Buy rating. This change reflects confidence in the company's growth prospects following its recent performance. The information comes from Stifel's research note issued on the same day.
Stifel's updated target suggests a potential upside for investors, considering the stock's recent trading price. Hinge Health shares closed at $111.17 on October 26, 2026, and as of the same day, they were trading around $111.40. This places the stock about 14.3% below the new analyst target. The shares have been performing well, trading above both the 50-day and 200-day moving averages, indicating strong momentum.
HNGE
Hinge Health, Inc.
Stifel vs. the S&P 500
Hypothetical returns from Stifel's disclosed trades, not real profit or advice. How we model this.
Other Institutional Activity in Hinge Health
Several other institutional investors have also adjusted their positions in Hinge Health. Assenagon Asset Management S.A. added 1,772,182 shares, bringing its total to 1,854,922 shares worth approximately $206.2 million. Two Sigma Investments, LP increased its holdings by 1,424,012 shares, ending with 1,807,895 shares valued at about $201 million. Conversely, 11.2 Capital Management, LLC reduced its stake by 1,239,923 shares, resulting in a total of 2,464,657 shares valued at about $274 million. Deer Management Co. LLC also decreased its holdings by 725,082 shares, leaving it with 1,908,707 shares worth roughly $212.2 million.
Hinge Health, Inc. Stock Up 1.3%
Hinge Health shares recently traded at about $111.40, which is above the 50-day moving average by 16.6% and the 200-day moving average by 70.4%. However, the stock remains about 1.8% below its 52-week high of $113.48. The stock's current price is also 1.7% below the average target price of $113.38 set by analysts, suggesting room for growth.
$HNGE price target
Hinge Health, Inc. daily closes and this analyst's $130 target. Not advice.
Recent Earnings
Hinge Health reported trailing twelve-month revenue of $720.1 million, showing a year-over-year growth of 53%. The company also achieved a net margin of 15.1%, reflecting its ability to manage costs effectively. The next earnings report is scheduled for November 2, 2026, where investors will be looking for updates on financial performance and future guidance.
Insider Buying and Selling at Hinge Health, Inc.
Insider trading activity at Hinge Health includes several notable transactions. On October 12, 2026, Chief Financial Officer James W. Budge sold 47,720 shares, valued at approximately $4.9 million. Earlier, on October 6, 2026, CEO Daniel Antonio Perez sold 4,100 shares at an average price of $100.20, totaling around $410,811. Additionally, President James Pursley sold 33,000 shares worth about $3.1 million on September 21, 2026. These transactions were made before the recent analyst call and do not indicate any planned insider purchases.
Analysts Set New Price Targets
On October 26, 2026, Stifel maintained its Buy rating and raised its price target for Hinge Health to $130 from $115. This is part of a broader trend, as other firms have also recently reaffirmed their ratings, including Keybanc, which has set a target of $140. The consensus among analysts suggests a positive outlook for Hinge Health, with a mean target price of $113.38 based on 16 analyst opinions.
About Hinge Health
Hinge Health, Inc. is a healthcare technology company based in San Francisco, CA. It focuses on delivering care for musculoskeletal health through its innovative platform, which includes AI-powered motion tracking and a proprietary nerve stimulation device. The company primarily serves self-insured employers, aiming to improve the delivery of care and patient outcomes.
Bottom Line
Investors will be watching Hinge Health closely as it prepares for its next earnings report on November 2, 2026. With Stifel's price target increase and other analysts maintaining positive ratings, the stock's performance in the coming weeks will be of interest, particularly given its strong revenue growth and upcoming financial updates.
Related Filing Alerts
Source: Stifel's rating change on $HNGE (Oct 26, 2026). Written by software, not financial advice. How we make alerts